Abstract
Introduction: The objective of the study was to assess the rate of canine retraction and secondary outcomes associated with conventional fixed orthodontic treatment (CFO) and CFO with micro-osteoperforation (CFO + MOP), that is, anchorage loss, root resorption, vitality of tooth, pain and discomfort level during the procedure. Methods: A total of 16 patients with Class II Division 1 malocclusion who required upper first premolar extraction with lower non-extraction/single incisor extraction were divided into the test group (MOP) and positive control group (CFO + MOP) for a split-mouth study. Both maxillary canines were retracted with nickel–titanium (NiTi) closed coil springs. Patients were reviewed after 24 hours, 7 days, 28 days, and 4, 8, and 16 weeks to assess the rate of tooth movement, anchorage loss, root resorption, vitality of tooth, pain and discomfort level. Results: There was a statistically significant difference in the rate of tooth movement between the CFO and CFO + MOP groups after the first 4 weeks ( P-value = .026), whereas no statistically significant difference was observed at 8, 12, and 16 weeks ( P-value = .33, .99, and .08, respectively). In the CFO group, there was no statistically significant difference in tooth movement between different time intervals ( P-value > .05). There was no significant difference in root resorption between the groups. The pain level was higher in the MOP group in the first 24 hours ( P-value < .05) after the procedure. Later on, the difference in pain level between the groups was not significant ( P-value > .05). The vitality of retracted canines in both groups was healthy. Conclusion: The study recommends that the CFO + MOP procedure has substantial potential to be used as an adjunct to the routine mechanotherapy for faster tooth movement, as it may reduce the treatment time by half in the first 4 weeks after the MOP procedure. There are no potential differences in anchorage loss, tipping, vitality, and apical and lateral root resorption between the CFO and CFO + MOP groups. This trial was registered at Clinical Trial Registry, India.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have